Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease.

Zinner, Ralph G; Glisson, Bonnie S; Fossella, Frank V; Pisters, Katherine M W; Kies, Merril S; Lee, Pamela M; Massarelli, Erminia; Sabloff, Bradley; Fritsche, Herbert A; Ro, Jae Y; Ordonez, Nelson G; Tran, Hai T; Yang, Ying; Smith, Terry L; Mass, Robert D; Herbst, Roy S

Zinner, Ralph G; Glisson, Bonnie S; Fossella, Frank V; Pisters, Katherine M W; Kies, Merril S; Lee, Pamela M; Massarelli, Erminia; Sabloff, Bradley; Fritsche, Herbert A; Ro, Jae Y; Ordonez, Nelson G; Tran, Hai T; Yang, Ying; Smith, Terry L; Mass, Robert D; Herbst, Roy S.

Affiliation

Zinner RG; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA. rzinner@mdanderson.org

Lung Cancer ; 44(1): 99-110, 2004 Apr.

Article in En | MEDLINE | ID: mdl-15013588

Subject(s)

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Carcinoma, Non-Small-Cell Lung / Receptor, ErbB-2 / Deoxycytidine / Lung Neoplasms Type of study: Diagnostic_studies / Prognostic_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Lung Cancer Journal subject: NEOPLASIAS Year: 2004 Document type: Article Affiliation country: Country of publication:

Search on Google

Add to My VHL

XML

PubMed Links